The 43rd Annual J.P. Morgan Healthcare Conference in 2025 showcased the accelerating progress of cell and gene therapies, reaffirming their transformative potential in modern medicine. Despite prior challenges, the field is now demonstrating tangible success, heralding a new era in treating complex and previously untreatable conditions.
One of the most promising developments came from Sana Biotechnology, which announced encouraging data from a first-in-human trial of its allogeneic cell therapy for type 1 diabetes. Remarkably, this therapy was administered without the need for immunosuppression, a long-standing barrier in transplantation therapies. This breakthroug...
